

NOCIL Ltd.

COVID-19 impacted performance, Strong recovery in sight

Q1FY21 revenue of NOCIL Ltd de-grew by 53.6% YoY to Rs1065mn, severely impacted due to lockdown in the country which led to temporary shutdown of the operations which led to decline in volumes. However, realizations remained fairly stable. Gross margins contracted sharply by 760bps to 48.8% in Q1FY21. EBITDA margin reported contraction of 1715bps to 7.5% YoY (vs our estimate of 9.5%) led by sharp gross margin contraction. Overall, EBITDA de-grew by 85.9% YoY to Rs80mn (vs our estimate of Rs106mn). This was majorly due to decline in revenues. Other income grew by 315% to Rs107mn and company reported tax credit of 263mn on the back of Rs515mn as write back of excess provisions relating to earlier years. Higher than expected other income and tax credit led PAT to witness a de-growth of 63.7% YoY to Rs120mn (vs our estimate of Rs28mn) in Q1FY21. We believe that the performance of Q1FY21 does not represent a normal quarter and thus comparing with previous quarter numbers will not give a correct picture.

Sharp decline in EBITDA margins, Good recovery expected in the coming quarters

- The company reported gross margin contraction of 760bps to 48.8% and EBITDA margin contraction of 1715bps to 7.5% in Q1FY21. The decline in margins is due to unfavorable input cost movement led by global crude oil prices and lower absorption of fixed cost.
- Despite adverse impact led by COVID-19 and lockdown on the volumes in Q1FY21, gradual recovery has been witnessed in demand and pick up in utilization post lifting of lockdown.
- Although, sequential recovery would be good for the company, it would be noteworthy to watch the demand sustenance from the auto and tyre sector going ahead.

Capacity expansion to lead healthy volume growth going ahead

- Considering the growing demand of rubber chemicals and limited headroom for volume growth, the company is already nearing the completion of its expansion plans.
- The company has started production from phase 1 capacity and phase 2 expansion is set to start commercial production by Q3FY21E. The cumulative capex of Rs 4.5bn has been completely incurred through internal accruals.
- Post expansion, management is focussed on increasing its volume and market share in the exports front. The company has penetrated further its reach in US market and they are witnessing good number of enquiries. They are confident of increasing wallet share from their existing clients post complete expanded capacity comes on stream.

Valuation

- We feel that impact of ADD removal and operating deleverage which led to margin decline are behind now. As the company operates in niche product segment with high entry barriers having market leadership, there is huge possibility of growth.
- Currently, the stock is trading at FY22E P/E of 17.2x and EV/EBITDA of 9.7x. We value the stock on forward EV/EBITDA multiple of 9.2x and arrive at target price of 126 per share which indicates downside of 4.9% from current level. Hence, we maintain **HOLD** rating.

Y/E Mar (Rs mn)	Q1FY21	Q1FY20	YoY (%)	Q4FY20	QoQ (%)
Net sales	1,065	2,296	-53.6%	2,127	-49.9%
Operating costs	985	1,730	-43.0%	1,761	-44.0%
EBITDA	80	566	-85.9%	366	-78.2%
EBITDA Margin (%)	7.5%	24.6%	(1715) bps	17.2%	(972) bps
Depreciation	92	80	14.8%	95	-3.5%
Interest	3	3	-21.9%	4	-28.6%
Other income	107	26	314.7%	31	244.2%
Exceptional	0	0	NA	0	NA
PBT	93	509	-81.7%	299	-68.8%
Provision for tax	-26	180	NA	80	-132.8%
Reported PAT	120	329	-63.7%	219	-45.4%

Y/E Mar (Rs mn)	Revenue	YoY (%)	EBITDA	EBITDA (%)	Adj PAT	YoY (%)	EPS (Rs)	RoE (%)	RoCE (%)	P/E (x)	EV/EBITDA (x)
FY18	9,676	30	2,654	27.4	1,699	75	10.4	20.7	20.5	14.8	8.5
FY19	10,429	8	2,927	28.1	1,849	9	11.2	16.7	16.7	15.1	9.0
FY20	8,463	-19	1,782	21.1	1,307	-29	7.9	11.1	11.2	13.4	9.6
FY21E	7,640	-10	1,268	16.6	849	-35	5.1	7.0	7.0	25.8	15.7
FY22E	10,413	36	1,981	19.0	1,269	49	7.7	10.0	10.0	17.2	9.7

Source: Company, EISEC Research Estimates



East India Securities Ltd
Excellent | Investment | Solutions

Rating: **HOLD** Upside/(Downside): (5%)

Current Price: Rs 132 Target Price: Rs 126

| Market data

Bloomberg:	NOCIL: IN
52-week H/L (Rs):	134 / 45
Mcap (Rs bn/USD mn):	21.7/ 292
Shares outstanding (mn):	165.6
Free float:	65.70%
3 Month Avg. daily vol (mn):	3.0
Face Value (Rs):	10
Group:	S&P BSE 500

Source: Bloomberg, EISEC Research

| Shareholding pattern (%)

	Jun-20	Mar-20	Dec-19	Sep-19
Promoter	34.3	33.7	33.7	33.7
FIIs	1.8	2.2	2.3	3.1
DIIIs	3.9	3.5	2.9	4.1
Public/others	60.0	60.5	61.0	59.0

Source: BSE

| Price performance (%)*

	1M	3M	12M	36M
S&P BSE 500	5.4	23.0	6.3	10.1
NOCIL	21.3	58.0	49.8	-2.9

*as on 25th Aug 2020; Source: AceEquity, EISEC Research

Aditya Khetan

Equity Research Analyst
+91 22 6192 5343
adityak@eisec.com

Awanish Chandra

Head of Research
+91 22 6192 5345
awanishc@eisec.com

Analyst call highlights:

- **Demand outlook:** Management has stated that demand of rubber chemical has witnessed good recovery post lifting of lockdown. Demand is expected to increase in the long term with subsequent pick up in auto and tyre sector. The month of June and July has witnessed gradual pick up in demand. However, they key to watch would be the sustainability of the same over the coming months.
- **Production volume:** Management stated company witnessed almost 50% of Q4FY20 volumes in Q1FY21. The volumes were impacted due to lockdown imposed in the country and across the globe. The manufacturing facilities were shutdown during April and early May & operations has resumed from 8th May 2020. Post starting of operations, the production volume was ramped up MOM basis and currently the company is running at higher levels as compared to July 2020 onwards.
- **Phase 2 capacity expansion:** The company has already started production from phase 1 expansion of Rs1.7bn and expects the phase 2 expansion of Rs2.8bn to commercialize by Q3FY21E. Depreciation run rate post complete expansion would be Rs450-460mn per annum.
- **Sequential improvement in EBITDA margins:** As Q1FY21 was an exceptional quarter, management stated that EBITDA margins and absolute EBITDA would increase sequentially from Q2FY21E led by increasing utilization and robust demand.
- Management stated the new capacity would take 4-4.5 years to reach peak utilization levels. The capex of Rs4.5bn would give approx. 1.8-1.85x asset turnover at current realization levels.
- **Positive development towards Anti-Dumping Duty (ADD):** The government of India is in the final stages of investigation of the ADD case and there are chances that ADD will be re-imposed. The ADD filed is on Anti-Oxidant PILFLEX-13. Overall, Anti-Oxidant segment contributes 45% to revenues and PILFLEX-13 has a major pie in Anti-Oxidant segment. We believe If ADD is re-imposed on PILFLEX-13, it would be game changer for NOCIL and would lead to improvement in margins of around 200-300bps.
- **Raw Material:** In the overall raw materials mix, the company procures 50% of raw materials from domestic and 50% is imports. Aniline is the major raw material and is available in plenty. Overall, there is no disruption in raw material supply chain post lifting of lockdown. Also, dependence on China for raw materials is very limited.
- **Tyre sector outlook:** Management stated that auto and tyre sector is picking up gradually post lifting of lockdown. Although, near term challenges continue to haunt the sector but the long-term growth outlook is intact. Replacement demand which constitutes 60-70% of tyre sector has witnessed robust pick up. We believe that probably tyre sector has bottomed out and surge in demand is on the cards. Major tyre players are also increasing utilization levels post lifting of lockdown to cater to increasing demand.
- **Global recognition from international customers:** Management stated that global customers has re-classified NOCIL from regional to global supplier. We believe this will help the company to gain larger visibility in the global rubber chemicals space going ahead.
- **Strategy going ahead:** Management has clearly stated that they are focussing on improving market share on the back of increased volumes from the expanded capacity going ahead.


Valuation and Recommendations

Considering the market leadership in rubber chemicals, backward integrated, focus on specialized products, high entry barriers etc, we believe NOCIL will gain strong foothold in the global rubber chemical space going ahead.

We value the stock on forward EV/EBITDA multiple of 9.2x and arrive at target price of 126 per share which is a downside of 4.9% from current valuations. We assign **HOLD** rating on the stock.


Risk to our call is unforeseen impact on the demand which could impact earnings, increasing the lockdown and substantial volatility in crude oil prices.

Fig 1: 1-year forward P/E chart



Source: AceEquity, EISEC Research

Fig 2: 1-year forward EV/EBITDA chart



Source: AceEquity, EISEC Research

Quarterly financials, operating metrics and key performance indicators

Fig 3: Consolidated Quarterly Financials

Y/E March (Rs mn)	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21
Net Sales	2,720	2,612	2,416	2,296	2,097	1,943	2,127	1,065
Raw Materials	1,194	1,175	1,109	1,002	887	927	1063	546
Employee Costs	163	154	189	205	184	194	175	165
Other Expenditure	574	558	519	523	548	457	523	275
EBITDA	789	725	599	566	485	366	366	80
Depreciation	56	56	67	80	80	83	95	92
Interest	1	1	2	3	3	3	4	3
Other Income	32	20	24	26	21	14	31	107
PBT	764	688	554	509	422	294	299	93
Tax	236	242	192	180	-128	84	80	-26
Tax rate (%)	31	35	35	35	-	29	27	-
PAT	528	447	362	329	549	210	219	120
Y-o-Y Growth (%)								
Revenue	19.5	4.8	-12.4	-14.4	-22.9	-25.6	-12.0	-53.6
EBITDA	46.1	4.2	-30.2	-29.6	-38.6	-49.9	-38.9	-85.9
PAT	38.8	-0.7	-29.8	-35.6	3.9	-53.3	-39.6	-63.7
Q-o-Q Growth (%)								
Revenue	1.5	-4	-7.5	-5	-8.7	-7.4	9.4	-49.9
EBITDA	-1.1	-8.1	-18.5	-4.9	-14.3	-24.5	5.5%	-78.2
PAT	4	-15.5	-19.9	-8.6	66.9	-61.8	4.2	-45.4
Margin (%)								
EBITDA	29	27.8	24.5	24.7	23.1	18.8	17.2	7.5
PAT	19.4	17.1	14.8	14.3	26.2	10.8	10.3	11.2

Source: AceEquity, EISEC Research

Fig 4: Key Assumptions

Operating Details	FY18	FY19	FY20P	FY21E	FY22E
Total volume (in MT)	40598	41816	40240	37179	48263
YoY Change (%)	12.5	3.0	-3.8	-7.6	29.8
Net realization (Rs/kg)	236	245	208	203	214
YoY Change (%)	8	4	-15	-2	5

Source: EISEC Research Estimates

Financial Statements

Profit & Loss	FY18	FY19	FY20	FY21E	FY22E
YE March (Rs mn)					
Revenues	9,676	10,429	8,463	7,640	10,413
% Growth	30.4	7.8	-18.9	-9.7	36.3
Raw Materials	4,406	4,668	3,878	3,648	4,995
% of sales	45.5	44.8	45.8	47.8	48.0
Employee	712	705	767	808	855
% of sales	7.4	6.8	9.1	10.6	8.2
Other Expenses	1,904	2,129	2,035	1,915	2,582
% of sales	19.7	20.4	24.0	25.1	24.8
EBITDA	2,654	2,927	1,782	1,268	1,981
EBITDA Margin %	27.4	28.1	21.1	16.6	19.0
Depreciation	240	243	337	364	441
EBIT	2414	2684	1445	904	1541
Finance cost	12	6	13	5	5
PBT from operat	2,402	2,678	1,432	899	1,536
Other Income	146	100	92	194	159
PBT	2,547	2,777	1,523	1,093	1,694
Tax-Total	848	929	217	244	426
Tax Rate (%)	33.3	33.4	14.2	22.3	25.1
Reported PAT	1,699	1,849	1,307	849	1,269
Extraordinary	-	-	-	-	-
Minority Interest	-	-	-	-	-
Adjusted PAT	1,699	1,849	1,307	849	1,269
PAT Margin	17.6	17.7	15.4	11.1	12.2
% Growth	75.0	8.8	-29.3	-35.0	49.5

Source: Company, EISEC Research Estimates

Key Ratios	FY18	FY19	FY20	FY21E	FY22E
YE March					
Growth ratios (%)					
Revenue	30	8	-19	-10	36
EBITDA	67	10	-39	-29	56
Adjusted PAT	75	9	-29	-35	49
Margin Ratios (%)					
EBITDA	27.4	28.1	21.1	16.6	19.0
PBT from operations	24.8	26.6	18.0	14.3	16.3
Adjusted PAT	17.6	17.7	15.4	11.1	12.2
Return Ratios (%)					
ROE	20.7	16.7	11.1	7.0	10.0
ROCE	20.5	16.7	11.2	7.0	10.0
ROIC	26.3	17.4	10.7	7.7	11.5
Turnover Ratios (days)					
Gross block turnover ratio (x)	1.4	1.2	0.8	0.7	1.0
Debtors	90	81	88	100	90
Inventory	129	133	128	135	130
Creditors	96	77	84	105	90
Cash conversion cycle	123	138	132	130	130
Solvency Ratio (x)					
Net debt/equity	0.0	0.0	0.0	0.0	0.0
Debt-equity	0.0	0.0	0.0	0.0	0.0
Interest coverage ratio	210	442	116	201	341
Gross debt/EBITDA	0.0	0.0	0.0	0.0	0.0
Current Ratio	4.1	3.8	3.0	4.1	4.7
Per share Ratios (Rs)					
Adjusted EPS	10.4	11.2	7.9	5.1	7.7
BVPS	63.6	70.3	71.6	74.2	78.9
CEPS	11.8	12.6	9.9	7.3	10.3
DPS	2.5	2.5	2.5	2.5	3.0
Dividend payout %	24%	22%	32%	49%	39%
Valuation (x)					
P/E (adjusted)	14.8	15.1	13.4	25.8	17.2
P/BV	2.4	2.4	1.5	1.8	1.7
EV/EBITDA	8.5	9.0	9.6	15.7	9.7
Dividend yield %	1.6	1.5	2.4	1.9	2.3

Source: Company, EISEC Research Estimates

Balance Sheet	FY18	FY19	FY20	FY21E	FY22E
YE March (Rs mn)					
Equity Share Capital	1645	1654	1656	1656	1656
Reserves & Surplus	8822	9976	10196	10631	11403
Shareholders' Fund	10467	11630	11852	12287	13059
Total Debt	50	0	92	63	57
Deferred Tax Liabilities	1041	1094	927	837	1140
Other Liabilities	159	151	168	177	187
Total Liabilities	11717	12875	13039	13364	14444
Gross Block	6935	8456	10193	10393	10493
Less: Accumulated Depre	1690	1913	2236	2600	3040
Net Block	5245	6542	7957	7793	7452
Capital WIP	425	1313	1563	525	420
Intangible assets	28	23	13	13	13
Long term Investments	529	232	245	261	272
Other Non-Current Asset	354	474	389	379	452
Total Non-Current Asset	6579	8585	10167	8971	8609
Inventories	1553	1707	1364	1349	1779
Current Investments	2288	1045	304	804	1054
Trade receivables	2434	2322	2032	2093	2568
Cash and cash equivalent	320	424	138	1169	1570
Other current assets	137	340	417	419	457
Total Current Assets	6732	5838	4256	5833	7428
Trade payables	1157	983	896	1049	1232
Other current liabilities	362	499	420	320	285
Short term Provisions	76	66	67	71	75
Total Current Liabilities	1594	1548	1383	1440	1592
Net Current Assets	5138	4290	2872	4393	5835
Total Assets	11717	12875	13039	13364	14444

Source: Company, EISEC Research Estimates

Cash Flow	FY18	FY19	FY20	FY21E	FY22E
YE March (Rs mn)					
Operating profit before WC changes	2,710	2,941	1,785	1,462	2,140
Changes in working capital	-876	-420	523	-85	-549
Tax Paid	-806	-881	-513	-244	-426
Cash flow from operations	1,028	1,641	1,794	1,133	1,165
Adj. OCF (OCF - Interest)	1,016	1,634	1,781	1,128	1,160
Capex	-127	-1,536	-1,739	-200	-100
Adj. FCF	889	98	42	928	1,060
Cash flow from investments	-1,423	-1,007	-1,065	322	-256
Cash flow from financing	-422	-502	-1,008	-425	-507
Net change in cash	-817	131	-278	1,030	402

Source: Company, EISEC Research Estimates

Disclaimer

East India Securities Limited (hereinafter EISEC), a publically listed company, registered as Research Analyst with SEBI (Registration No. INH300003231). EISEC is engaged in broking services, distribution and marketing of financial products, and in the normal course of business, EISEC prepares and shares research data and reports periodically with clients, investors, stake holders and general public in compliance with Securities and Exchange Board of India Act, 1992, Securities And Exchange Board Of India (Research Analysts) Regulations, 2014 and/or any other applicable directives, instructions or guidelines issued by the Regulators from time to time.

Research report is a written or electronic communication that includes research analysis, research recommendation or an opinion concerning securities or public offer, providing a basis for investment decisions. The views expressed therein are based solely on information available publicly/internal data/other reliable sources believed to be true. The information is provided merely as a complementary service and do not constitute an offer, solicitation for the purchase or sale of any financial instruments, inducement, promise, guarantee, warranty, or as an official confirmation of any transactions or contract of any kind.

Research data and reports published/ emailed/ text messaged via Short Messaging Services, Online Messengers, WhatsAppetc/transmitted through mobile application/s, including but not limited to FLIP™, Video Widget, telephony networks, print or electronic media and or those made available/uploaded on social networking sites (e.g. Facebook, Twitter, LinkedIn etc) by EISEC or those recommendation or offers or opinions concerning securities or public offer which are expressed as and during the course of “Public Appearance” are for informational purposes only. The reports are provided for assistance and are not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Though disseminated to clients simultaneously, not all clients may receive the reports at the same time. EISEC will not treat recipients as clients by virtue of their receiving this report.

The reports include projections, forecasts and other predictive statements which represent EISEC’s assumptions and expectations in the light of currently available information. These projections and forecasts are based on industry trends, circumstances and factors which involve risks, variables and uncertainties. The actual performance of the companies represented in the report may vary from those projected. The projections and forecasts described in this report should be evaluated keeping in mind the fact that these-

- are based on estimates and assumptions
- are subject to significant uncertainties and contingencies
- will vary from actual results and such variations may increase over a period of time
- are not scientifically proven to guarantee certain intended results
- are not published as a warranty and do not carry any evidentiary value.
- are not based on certain generally accepted accounting principles
- are not to be relied on in contractual, legal or tax advice.

Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Reports based on technical analysis is focused on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

Though we review the research reports for any untrue statements of material facts or any false or misleading information, , we do not represent that it is accurate or complete and it should not be relied on in connection with a commitment or contract whatsoever. Because of the possibility of human, technical or mechanical error by our sources of transmission of Reports/Data, we do not guarantee the accuracy, adequacy, completeness or availability of any information and are not to be held responsible for any errors or omissions or for the results obtained from the use of such information. EISEC and/or its Affiliates and its officers, directors and employees including the analysts/authors shall not be in any way responsible for any indirect, special or consequential damages that may arise to any person from any inadvertent error in the information contained in the reports nor do they take guarantee or assume liability for any omissions of the information contained therein. Information contained therein cannot be the basis for any claim, demand or cause of action. These data, reports and information do not constitute scientific publication and do not carry any evidentiary value whatsoever.

The reports are not for public distribution. Reproduction or dissemination, directly or indirectly, of research data and reports of EISEC in any form is prohibited except with the written permission of EISEC. Persons into whose possession the reports may come are required to observe these restrictions. Opinions expressed therein are our current opinion as of the date appearing on the report only. Data may be subject to update and correction without notice. While we endeavour to update on a reasonable basis the information discussed in the reports, there may be regulatory, compliance, or other reasons that prevent us from doing so.

The reports do not take into account the particular investment objectives, financial situations, risk profile or needs of individual clients. The user assumes the entire risk of any use made of this information. Each recipient of the reports should make such investigation as deemed necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in such reports (including the merits and risks involved).

Certain transactions - futures, options and other derivatives as well as non-investment grade securities - involve substantial risks and are not suitable for all investors. Investors may lose his/her entire investment under certain market conditions. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of investments referred to in research reports and the income from them may fluctuate. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options. Foreign currencies denominated securities are

subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. Investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk.

The recommendations in the reports are based on 12 month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/return/lack of clarity/event we may revisit rating at appropriate time. The stocks always carry the risk of being upgraded to buy or downgraded to a hold, reduce or sell. The opinions expressed in the reports are subject to change but we have no obligation to tell our clients when our opinions or recommendations change. The reports are non-inclusive and do not consider all the information that the recipients may consider material to investments. The reports are issued by EISEC without any liability/undertaking/commitment on the part of itself or any of its entities.

Recipients of the research reports should assume that entities of EISEC may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of the reports. We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of reports/data/material, may, from time to time have 'long' or 'short' positions in, act as principal in, and buy or sell the securities thereof of companies mentioned therein or be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as market maker in the financial instruments of the company/ies discussed therein or act as advisor or lender/borrower to such company/ies or have other potential conflicts of interests with respect to any recommendation and related information and opinions.

We further undertake that-


- No disciplinary action has been taken against the research analyst or EISEC by any authority in connection with their respective business activity.
- EISEC, Research analysts, persons reporting to research analysts and their relatives may have financial interests and material conflict of interest in the subject company.
- EISEC, Research analysts, persons reporting to research analysts and their relatives may have actual/beneficial ownership of 1% or more in the subject company's securities, at the month immediately preceding the date of publication of this research report.

Past performance is not a guide for future performance, future returns are not guaranteed and investors may suffer losses which may exceed their original capital.

The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. Distributing/taking/sending/dispatching/transmitting this document in certain foreign jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe any such restrictions. Failure to comply with this restriction may constitute a violation of any foreign jurisdiction laws.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets.

NOCIL Ltd.



Source: ACEEquity, EISEC Research

Analyst holding in stock: **NO**

Key to EISEC Investment Rankings

Buy: Upside by >15%, Accumulate: Upside by 5% to 15%, Hold: Downside/Upside by -5% to +5%, Reduce: Downside by 5% to 15%, Sell: Downside by >15%

East India Securities Ltd. (<http://www.eisec.com/>)

Office: - 201, Garnet Palladium, Pandit Motilal Nehru Marg, Panch Bawadi, Behind Express Zone, Malad East, Mumbai – 400097

Disclosure of Interest Statement		
1	Business activities of East India Securities Ltd (EISEC)	East India Securities Ltd (hereinafter referred to as "EISEC") is a registered member of NSE (All Segments), MCX-SX (Currency Derivatives Segment) and BSE (All segments), Depository Participant of NSDL & CDSL.
2	Details of Disciplinary History of EISEC	EISEC has not been debarred/ suspended by SEBI or any other regulatory authority from accessing or dealing in securities market on behalf of clients.
3	Registration status of EISEC:	EISEC is registered with SEBI as a Research Analyst (SEBI Registration No INH300003231)
		NOCIL Ltd.
4	Whether Research analyst's or relatives' have any financial interest in the subject company and nature of such financial interest	No
5	Whether Research analyst or relatives have actual / beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the document.	No
6	Whether the research analyst or his relatives has any other material conflict of interest	No
7	Whether research analyst has received any compensation from the subject company in the past 12 months and nature of products / services for which such compensation is received	No
8	Whether the Research Analyst has received any compensation or any other benefits from the subject company or third party in connection with the research report	No
9	Whether Research Analysts has served as an officer, director or employee of the subject company	No
10	Whether the Research Analyst has been engaged in market making activity of the subject company.	No
11	Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past twelve months;	No
12	Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;	No
13	Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;	No

Member (NSE and BSE)

Single SEBI Regn No.: INZ000190836

Research Analyst

SEBI Registration No. INH300003231

Website: www.eisec.com

Investor Grievance Email ID: mail@eisec.com

Compliance Officer Details:

Sumeet Kejriwal 033-40205901; Email ID: sumeetk@eisec.com

East India Securities Ltd. (CIN: U67120WB1995PLC072026)	
Registered Office Address	Corporate Office & Correspondence Address
DA-14, Saltlake City, Sector-1, Kolkata-700064	201, Garnet Palladium, Pandit Motilal Nehru Marg, Panch Bawadi, Behind Express Zone, Malad East, Mumbai – 400097